June 21-22, 2018 Rome, Italy Key Topics : Pre-Clinical and Clinical Trials, Adverse Drug Reactions, Pharmacovigilance and Risk Management, Good Pharmacovigilance Practice, Pharmacy Practices and its Challenges, Biopharmaceutical Sciences, Clinical Trials on Various Disorders, Data Quality Management and Analysis, Pharmacovigilance Significance & Scope, Diversity in Industrial Clinical Trials and Clinical Research, Clinical Research and Statistics, Case Report in Clinical Trials, Drug Safety, Clinical Data Base Management, PV Consultings and Business Opportunity, Regulatory Affairs, Entrepreneurs Investment Meet,
This is an open access book. The International Conference of Green Technology (ICGT) is an annual multidisciplinary forum for promoting and fostering interactions between researchers, scientists, academia, and related industrial communities in studying the development of science and green technology. These conferences introduce newcomers to the field, keep practitioners aware of current developments, and provide unparalleled networking opportunities. Innovative science and technology must be developed to offered solutions for new normal adaptation in Post pandemic life in all fields. Therefore, “Empowering innovative science and technology for future environmental perspective” become the main topic of The 12th ICGT 2022. Considering the uncertainty of the COVID-19 outbreak, The 12th ICGT 2022 was held fully hybrid on October 26-27, 2022. The scientific programs will include keynote lectures, plenary lectures and invited lectures in parallel sessions. All participants will have virtual access to join the conferences and all authors will have opportunities to present work either virtually or on-site, in Malang Indonesia.
This new volume of Advances in Pharmacology explores the current state of antiviral agents. Chapters cover such topics as virus entry inhibitors, interferon-free drug combinations, and antiviral agents for HSV. With a variety of chapters and the best authors in the field, the volume is an essential resource for pharmacologists, immunologists and biochemists alike. - Explores the current state of anti-viral agents - Chapters cover a variety of topics such as virus entry inhibitors, interferon-free drug combinations, and antiviral agents for HSV - With the best authors in the field, the volume is an essential resource for pharmacologists, immunologists and biochemists alike
The fourth volume of Advances in Antiviral Drug Design is keeping up with the recent progress made in the broad field of antiviral drug research and encompasses six specific directions that have opened new avenues for the treatment of HIV and other virus infections.First, as the introductory chapter, the different new anti-HIV agents that are now in preclinical or clinical development are reviewed by E. De Clercq. This includes new NRTIs, NNRTIs and PIs, but also HIV entry/fusion inhibitors as well as integrase inhibitors, and some of these agents, such as the NRTI emtricitabine [(-)FTC] and the PI atazanavir, may soon be licensed for clinical use.Second, high expectations are vested in the potential therapeutic usefulness of inhibitors of HIV integration, a point of no return in the life cycle of HIV, and this approach is highlighted by D.J. Hazuda and S.D. Young.Third, as all currently available PIs can be described as "peptidomimetic", and, therefore, expected to demonstrate overlapping virus-drug resistance and side effect profiles, it would be interesting to see how a non-peptidic protease inhibitor such as tipranavir behaves, and this is covered by D. Mayers, K. Curry, V. Kohlbrenner and S. McCallister.Fourth, neuraminidase inhibitors such as zanamivir (that has to be inhaled) and oseltamivir (that can be administered via the oral route) have gained a definitive status as antiviral drugs useful for both therapy and prophylaxis of influenza A and B virus infections; as they target a specific influenza viral enzyme, neuraminidase (or sialidase), they may be expected to block newly emerging influenza viruses as well, and the design of neuraminidase inhibitors has received due attention of H. Jin and C.U. Kim.Fifth, while the major current efforts in antiviral drug development have shifted from herpesviruses towards HIV and hepatitis viruses [hepatitis B virus (HBV), hepatitis C virus (HCV)], it is interesting to note that by switching from the classical five-membered sugar or acyclic nucleoside strategy, J. Wang, M. Froeyen and P. Herdewijn have gone "upstream" in designing six-membered carbocyclic nucleosides as potential anti-herpesvirus agents.Sixth, following up on the nucleotide prodrug strategy introduced above under ix, to deliver the biologically active nucleotides inside the cells, C. Meier has elaborated on a particular class of such pronucleotides, namely that of the cyclosaligenyl pronucleotides, an approach that should have far reaching implications for compounds effective against HIV, HBV and other viruses.The six topics covered in this fourth volume of Advances in Antiviral Drug Design are in the front line of the present endeavors towards the design and development of new therapeutic agents for virus infections. They pertain to the combat against three of the most important viral pathogens of current times: HIV, HBV, influenza virus and herpesviruses.
September 11-12, 2017 Paris, France Key Topics : Gastroenterology, Digestive Diseases, Genetics and Molecular Biology in Gastroenterology, Gastrointestinal Complications in Diabetes, Gastrointestinal Cancers, Neuro Gastroenterology, Clinical Advances in Liver Diseases, Probiotics in Gastrointestinal Disorders, Microbiota in health and gastrointestinal disease, Pediatric Gastroenterology, Diets/Dietary habits (Nutrition) and Gastrointestinal Disorders:, Gastroenterology and Pregnancy,
